COVID-19 Notice: Novo Nordisk Information and Resources. Click here.

The science of obesity

The Obesity Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about the obesity disease state and obesity treatments. It provides evidence-based information on a variety of topics relevant to patient care. All information is for educational purposes only and is not intended to promote any products.

Disease education

Learn more about the condition that currently affects more than one-third of U.S. adults.1


Explore Content

Medical information

Access information and resources on each of our obesity products.


Explore Content

Congress materials

Access our library of recently presented posters, abstracts and presentations.


Explore Content

Recent Content

Disease Education

Obesity and COVID-19

Take a deep dive into the data and recommendations revealing how COVID-19 interacts with obesity and other disease states, gathered from a variety of expert sources.

Download PPTX
Download PDF

Medical Information

Overview of Current and Emerging Weight-Loss Pharmacotherapies (IME content)

Review outcomes and warnings for weight-loss medications currently approved by the FDA.

1. Prevalence of Obesity Among Adults and Youth: United States, 2011–2014. NCHS Data Brief, No. 219, November 2015.



Questions about obesity research or other disease states?

Speak to a live medical information specialist or submit a question via our web form.

Start Conversation

For other therapeutic areas, visit our Novo Nordisk Medical website.

Visit Site

This content is intended for education only. Any unauthorized copying or distribution of this document or the information it contains is strictly prohibited.



You are now leaving the Novo Nordisk Obesity Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.